Case Study: Massachusetts-based therapeutics company accelerates AML target assessment with Elucidata’s Polly

Massachusetts-based Therapeutics Company assesses AML targets 3X faster with Elucidata

A Massachusetts-based therapeutics company sought to accelerate its assessment of AML targets using differentiation therapy but faced significant challenges in finding and harmonizing molecular and clinical data from numerous public and in-house sources. To overcome this, they partnered with Elucidata and used its Polly platform.

Elucidata’s Polly automated the data ingestion, harmonization, and knowledge graph-driven analysis, which provided a 360-degree view of disease biology. As a result, the company assessed 10 AML targets in just 6 months, a process that traditionally takes 15-24 months. Elucidata's solution also achieved a 3X reduction in report generation costs and improved the probability of early discovery success from 1:2000 to 1:5.